Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
Date:1/29/2009

CRANBURY, N.J., Jan. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) will announce fourth quarter and full year 2008 financial results after the regular close of markets on Thursday, February 5, 2009. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m. EST.

Interested participants and investors may access the conference call at 5 p.m. EST by dialing 877-675-4756 (U.S./Canada) or 719-325-4870 (international). A telephonic replay of the call will be available for seven days beginning at 8 p.m. EST. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 8627644.

An audio webcast can also be accessed via the investor section of the Amicus Therapeutics Web site at www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, an audio webcast replay will remain available in the Investors section of the Amicus Therapeutics Web site for 30 days.

Amicus' press releases are available at www.amicustherapeutics.com

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

FOLD -G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
2. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
3. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
4. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
5. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
6. Amicus Therapeutics Opens Research Facility in San Diego
7. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
8. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
9. Amicus Therapeutics Announces First Quarter 2008 Financial Results
10. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
11. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research ... Inc. has been selected for membership in ARCS Alumni Hall of Fame ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
Breaking Biology Technology:
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/24/2017)... March 24, 2017 The Controller General of Immigration ... Abdulla Algeen have received the prestigious international IAIR Award for ... Continue Reading ... ... Deputy Controller Abdulla Algeen (small picture on the right) have received the ...
Breaking Biology News(10 mins):